A recent work published in the journal Expert Review of Vaccines places Spain as the second country within the European Union with best application of your children’s calendar.
The work, carried out by a group of European vaccinologists, including a member of the Spanish Association of VaccinologyrIt selects all vaccines included in children’s calendars, recommended or financed, assigning a ‘basic’, ‘extended’ and ‘increased’ score. The first group includes tetanus, diphtheria, measles, rubella, mumps, whooping cough, hepatitis B, Hib, pneumococcus, tuberculosis, rotavirus, meningococcus and papillomavirus. The second included chickenpox and flu and the third included universal vaccination against the latter two, the HPV vaccine for both sexes, the hexavalent vaccine vs. the pentavalent vaccine, the tetravalent antimeningococcal vaccine, the vaccine against N meningitidis serogroup B, and the quadrivalent vs. trivalent flu vaccine. .
In the total count, Spain occupies second place after Latvia, but with the exception that the work was done before the decision was made to introduce the rotavirus vaccine in our country and, furthermore, the inclusion of monoclonal antibodies against the respiratory syncytial virus was not taken into account.
The objective of the work is to study the breadth of protection of the National Immunization Programs (NIP) throughout Europe varies, and for this proposes a framework to assess the comprehensiveness of pediatric NIPs in Europe.
As a result of them, a division into three levels of all countries was established. For them, the number of preventable diseases covered by each Plan, the simplification of the vaccination schedule, the reinforcement of protection by increasing the serotype, and the degree of financing were used as criteria.
The evaluation noted as countries with the More complete PINs to France, Italy, Latvia and Spain. All Tier 1 countries recommended and funded at least 12 of the 14 antigens included in the reference group, and Latvia and Spain recommended and funded both antigens in the expanded group.
For Italy and France, although they only recommended and funded one expanded antigen, they recommended 13 and 14 reference group antigens, respectively. Furthermore, all countries achieved high improvement scores, with Spain, Italy and Latvia having the three highest improvement scores among the European countries evaluated (4.43, 4.43 and 4.05, respectively). Italy and Latvia achieved the maximum improvement scores in all criteria except strengthening protection by increasing serotypes/serogroups. They received maximum improvement score assignment based on their gender-neutral HPV vaccination, universal rotavirus vaccination, and use of the hexavalent vaccine.
Tier 2 contained the largest number of countries of all tiers (n = 15; Austria, Belgium, Bulgaria, Cyprus, Finland, Germany, Greece, Hungary, Ireland, Lithuania, Netherlands, Poland, Slovenia, Switzerland, and the United Kingdom ). Within Tier 2, most countries recommended and funded 12/13 reference antigens, with the exception of Lithuania, which recommended all 14 reference antigens, and Finland, which recommended and funded 11. Of the Tier 2 countries, 12 recommended at least one expanded antigen. , with the exception of Belgium, Lithuania and the Netherlands, which did not recommend or fund any expanded antigens. In contrast, Finland was the only Tier 2 country that recommended both extended antigens.
The least complete Tier 3 countries were Albania, Croatia, Czech Republic, Denmark, Estonia, Malta, Norway, Portugal, Romania, Serbia, Slovakia and Sweden. lCountries within Tier 3 often did not meet many improvement scoring criteria or recommend or fund many reference group antigens, resulting in lower scores than countries in Tiers 1 and 2. For example, within this level, the range in improvement scores was 1.05 to 2.55. and most countries recommended and funded fewer than 13 antigens in the reference group. Many countries require only small changes to their PINs to move from level 3 to level 2; Albania, the Czech Republic, Norway and Sweden are less than one point away from level 2. For example, Albania has one of the lowest improvement scores, 1.43 (assigned for the spread of rotavirus to a universal population, simplification of the schedule through combined use and strengthening protection by increasing serotypes/serogroups. Albania can therefore aim to improve improvement scores by extending recommended and funded vaccines to universal populations and adding vaccines from the expanded group to your PNI.
The objective of the work “is to open the debate on why there are differences between NIP scores and promote greater dissemination of the actions carried out by countries.” In addition, the PEDVAC evaluation can be used as a resource to highlight key areas in which European countries might wish to focus on to improve their current program with the aim of improving overall public health,” the authors note.
2024-03-10 12:00:29
#Spain #country #application #childhood #vaccination #schedule #diariofarma
